Experts examine heart benefits of diabetes drugs

11/14/2011 | Endocrine Today

An expert, presenting at the annual meeting of the American Heart Association, said trials have shown that SGLT2 inhibitors such as dapagliflozin help improve weight, lipid profile, and blood glucose and blood pressure levels in patients with diabetes. Other research has shown that the already FDA-approved drug acarbose and insulin-based diabetes therapies also have cardiovascular benefits for patients.

View Full Article in:

Endocrine Today

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA